Morgan Stanley lowered the firm’s price target on Elevance Health (ELV) to $551 from $643 and keeps an Overweight rating on the shares. The firm updated its model and valuation to reflect Q3 results and updated commentary from management on FY24 and the initial FY25 view.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $549 from $665 at Bernstein
- Elevance Health price target lowered to $501 from $622 at Barclays
- Elevance Health price target lowered to $484 from $589 at TD Cowen
- Elevance Health price target lowered to $478 from $585 at RBC Capital
- Elevance Health cut to Hold at Argus on earnings pressure in 2024-2025